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Abstract
Background: The involvement of secretoglobins (SCGBs) other than SCGB1A1 (Clara cell 10-kDa protein, CC10) in
human airway diseases remains unexplored. Among those SCGBs, SCGB3A2 (uteroglobin-related protein 1, UGRP1)
is particularly interesting, given its structure and function similarities with SCGB1A1 (CC10). The aim of this study
was to investigate the expression regulation of SCGBs other than SCGB1A1 (CC10) in human upper airway, and
their potential involvement, particularly that of SCGB3A2 (UGRP1), in chronic rhinosinusitis (CRS) with nasal polyps
(CRSwNP) and without nasal polyps (CRSsNP).
Methods: Eight SCGB family members including SCGB3A2 (UGRP1), SCGB1C1 (ligand binding protein RYD5),
SCGB1D1 (lipophilin A), SCGB1D2 (lipophilin B), SCGB1D4 (interferon-g inducible SCGB), SCGB2A1 (mammaglobin 2),
SCGB2A2 (mammaglobin 1), and SCGB3A1 (uteroglobin-related protein 2) were studied. The regulation of SCGBs
mRNA expression in normal nasal mucosa by proinflammatory, Th1, and Th2 cytokines was studied through nasal
explant culture. SCGBs mRNA expression levels in CRSsNP and CRSwNP patients and controls were compared. The
mRNA levels were detected by means of quantitative reverse transcriptase-polymerase chain reaction. The protein
expression of SCGB3A2 (UGRP1) was analyzed using immunohistochemistry.
Results: The expression of SCGBs except SCGB1D2 (lipophilin B) could be found in upper airway and be
differentially regulated by different cytokines. SCGB3A2 (UGRP1) mRNA expression was induced by Th1 cytokine,
but suppressed by proinflammatory and Th2 cytokines. SCGBs mRNA expression was altered in CRS; particularly,
SCGB3A2 (UGRP1) protein and mRNA expression was markedly decreased in both CRSsNP and CRSwNP and its
protein levels inversely correlated with the number of total infiltrating cells, preoperative sinonasal CT scores, and
postoperative endoscopy and symptom scores.
Conclusion: SCGBs except SCGB1D2 (lipophilin B) are expressed in human upper airway and their expression can
be differentially regulated by inflammatory cytokines. SCGBs mRNA expression is altered in CRS. Reduced
production of UGRP1, which is likely due, at least in part, to a local cytokine environment, may contribute to the
hyper-inflammation in CRS and correlates with response to surgery.
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Secretoglobin (SCGB) superfamily is a group of small,
secreted, dimeric proteins [1-5]. Our knowledge of the
SCGB superfamily is rapidly expanding with the discov-
ery of many new human genes. At present, nine mem-
bers of this superfamily have been identified in humans,
which includes SCGB1A1 (Clara cell 10-kDa protein,
CC10), SCGB1C1 (ligand binding protein RYD5, RYD5),
SCGB1D1 (lipophilin A, LIPA), SCGB1D2 (lipophilin B,
LIPB), SCGB1D4 (interferon-g inducible SCGB, IIS),
SCGB2A1 (mammaglobin 2, MGB2), SCGB2A2 (mam-
maglobin 1, MGB1), SCGB3A1 (uteroglobin-related pro-
tein 2, UGRP2), and SCGB3A2 (uteroglobin-related
protein 1, UGRP1) [1-5]. Although the expression of
SCGBs has generally been associated with secretory
epithelia, such as in the mammary gland and prostate,
there have been only few reports of their expression and
regulation in human and rodent airways [1-5].
The pathophysiological functions of SCGBs are poorly
understood. Limited studiesi n d i c a t et h a ts o m eS C G B s
are associated with malignancies, such as SCGB2A2
(MGB1), SCGB2A1 (MGB2), and SCGB1D1 (LIPA) [1,2],
and some are involved in immune responses, such as
SCGB1A1 (CC10), SCGB1D4 (IIS), SCGB3A1 (UGRP2),
and SCGB3A2 (UGRP1) [3-7]. CC10 is a prototypical
member of SCGB superfamily with anti-inflammatory
and immunomodulatory effects. Previous studies from us
and others have implicated the diminished expression of
CC10 in the pathogenesis of inflammatory upper and
lower airway diseases including chronic rhinosinusitis
(CRS) and asthma [5-8]. However, as to other SCGBs,
whether they are also involved in airway diseases has
been rarely studied.
Among SCGB family members, SCGB3A2 (UGRP1) is
particularly interesting. SCGB3A2 (UGRP1) possesses
significant amino acid sequence similarity to CC10
(SCGB1A1) [4,9]. Intranasal administration of recom-
binant adenovirus expressing SCGB3A2 (UGRP1)
suppresses the allergen-induced eosinophilic lung inflam-
mation in a mouse model, indicating that SCGB3A2
(UGRP1) may possess a similar anti-inflammatory func-
tion as SCGB1A1 (CC10) [9]. Genetic analysis has demon-
strated that a single nucleotide polymorphism (SNP)
(G/A) at -112bp of the human SCGB3A2 (UGRP1) gene
promoter is associated with an increased risk of asthma in
a Japanese population [10,11]. Nevertheless, the expression
and the role of SCGB3A2 (UGRP1) in human airway dis-
eases remain largely unknown.
CRS is a complex and heterogeneous syndrome and
typically classified into CRS with nasal polyps (CRSwNP)
and CRS without nasal polyps (CRSsNP) [12,13]. To
date, although the etiology and the pathogenesis of CRS
remain a matter of vigorous debate, the imbalance
between pro- and anti-inflammatory responses is
believed to initiate and sustain the inflammation exacer-
bation in CRS [5,7,12,13]. Therefore, indentifying the
factors influencing this imbalance would provide new
insights into the pathogenesis of CRS.
The purposes of the present study were: (1) to exam-
ine the regulation of SCGBs mRNA expression other
than SCGB1A1 (CC10) in human normal nasal mucosa
by inflammatory cytokines; (2) to compare the expres-
sion levels of SCGBs in normal controls and CRSwNP
and CRSsNP patients; and (3) to further study the
SCGB3A2 (UGRP1) protein expression and its signifi-
cance in CRS.
Methods
Subjects
This study was approved by the ethical committee of
Tongji Medical College of Huazhong University of
Science and Technology and conducted with written
informed consent from patients.
1. SCGBs expression regulation in ex vivo cultured
normal nasal mucosa study: This study population com-
prised 34 patients undergoing septal surgery and/or tur-
binectomy because of nasal obstruction. None had a
history of persistent mucopurulent drainage, allergic rhi-
nitis, or sinus disease. Inferior turbinate mucosal sam-
ples were used for nasal explant culture [5].
2. SCGBs expression in CRS study: Twenty patients
with CRSsNP and 20 patients with CRSwNP who had
bilateral CRS were recruited. The diagnosis of CRSsNP
and CRSwNP was made according to the current Eur-
opean EAACI Position Paper on Rhinosinusitis and
Nasal Polyps and American guideline [12,13]. Diseased
ethmoid sinus mucosa from the most hypertrophied and
hyperemic regions and NP tissues from the apex region
of polyps were collected during surgery. As controls,
inferior turbinate mucosal samples were taken during
surgery from 16 patients undergoing septoplasty and/or
turbinectomy because of nasal obstruction and not
having any sinus disease or allergic rhinitis. Surgical
samples were processed for histology, reverse transcrip-
tase-polymerase chain reaction (RT-PCR), and immuno-
histochemistry study.
In our study, subjects who had an antrochoanal polyp,
cystic fibrosis, fungal sinusitis, or primary ciliary dyskine-
sia were excluded. None of the patients had an acute
upper respiratory infection in the four weeks before the
operation. The atopic status was evaluated by skin prick
test to a standard panel of aeroallergens. The diagnosis of
asthma and aspirin sensitivity was based on history and
physician diagnosis. Oral glucocorticoid and intranasal
steroid sprays were discontinued at least 3 months and
1 month before surgery, respectively. None had received
antileukotrienes and immunotherapy. All patients and
controls were Han Chinese from central China.
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Assessment of CRS clinical severity
For CRS patients, preoperative coronal CT scans
through paranasal sinuses were obtained and scored
using the Lund-Mackay system, as previously described
[14]. Symptom evaluation and endoscopic examination
were taken before and 12 months after the surgery. A
symptom questionnaire based on a visual analog score
(VAS) of 0 to 10 according to severity was used. A total
VAS score was calculated based on the sum of five VAS
symptom domains, including nasal blockage, headache,
facial pain, alteration of sense of smell, and nasal dis-
charge [5]. In addition, patients were asked to rate his/
her overall burden of CRS symptoms [5]. Endoscopy
physical findings were scored according to Lanza and
Kennedy [15].
Nasal explant culture
Normal inferior turbinate mucosal tissues were obtained
during surgery and immediately cut into multiple frag-
ments of approximately 6 mm
3. One was processed for
histologic evaluation and others were used for tissue
culture. Sections of tissue were placed on 0.4 mm-well
inserts (Millipore Corp., Billerica, MA, USA) in 2 mL of
Dulbecco’s modified Eagle’s medium/F-12 supplemented
with 2 mM L-glutamine, 100 U/mL penicillin, and 100
mg/mL streptomycin (Invitrogen, Grand Island, NY,
USA). The tissue was oriented with the epithelium
being exposed to the air, forming an air-liquid interface
to mimic the in vivo situation [6,16,17]. For dose
response experiments, the tissues were incubated in the
presence of TNF-a (1, 10, and 100 ng/ml), IL-1b (1, 10,
and 100 ng/ml), INF-g ( 0 . 1 ,1 ,a n d1 0n g / m l ) ,I L - 4
(1, 10, and 100 ng/ml), or IL-13 (1, 10, and 100 ng/ml)
for 12 h. These cytokines were purchased from R&D
Systems (Minneapolis, MN, USA). For time course
experiments, the tissues were incubated with TNF-a
(20 ng/ml), IL-1b (20 ng/ml), IL-4 (20 ng/ml), IL-13
(20 ng/ml), or INF-g (1 ng/ml) for various time dura-
tions between 4 and 24 h. The tissues were cultured at
37˚C with 5% CO2 in humidified air.
Quantitative RT-PCR
Freshly obtained tissues were immediately snap frozen
in liquid nitrogen. RNA was extracted and cDNA was
reverse transcribe as previously described [16]. The PCR
assays for the members of SCGB family were performed
using the SYBR Premix Ex Taq kit [TaKaRa Biotechnol-
ogy (Dalian), Dalian, China] with appropriate primers
constructed from published sequences (Table 2) as men-
tioned elsewhere [16]. GAPDH was used as a house-
keeping gene for normalization and ‘no template’
sample was used as a negative control. Relative gene
expression was calculated by using the comparative CT
method [16]. An inferior turbinate sample was used as a
calibrator in SCGBs expression in CRS study, whereas
respective control tissues without any cytokine stimula-
tion were employed as calibrators for SCGBs expression
regulation study. The identity of PCR product was con-
firmed by DNA sequencing.
Routine staining, SCGB3A2 (UGRP1)
immunohistochemistry, and quantification
Paraffin sections (4 μm) were stained with hematoxylin
and eosin. The number of inflammatory cells per high-
power filed (HP) was determined by counting 10 ran-
domly selected fields in a blinded fashion at 400 × mag-
nification by 2 independent physician who were blind to
the clinical data. The difference in counting results
between 2 independent investigators was less than 10%.
In case of disagreement (the two counts differed by >
10%), a consensus was reached by reviewing the speci-
men at a multihead microscope by our research team.
As to immunohistochemical staining of SCGB3A2
(UGRP1) protein, the sections were stained with goat
anti-SCGB3A2 (UGRP1) antibody (1:100; R&D Systems).
SCGB3A2 (UGRP1) was detected using the streptavidin-
peroxidase complex method with a histostain-plus kit
(Zhongshan Golden Bridge Biotechnology, Beijing,
China) as previously described [16]. Color development
was achieved with 3’,3 ’-diaminobenzidine, which ren-
dered positive cells brown. A species-matched antibody
was used as a negative control. Quantitative measure-
ment of SCGB3A2 (UGRP1) protein expression was
Table 1 Clinical data of patients enrolled in SCGBs expression regulation study and SCGBs expression in CRS study
SCGBs expression in CRS study SCGBs expression regulation study
Control CRSsNP CRSwNP
Subject, n 16 20 20 34
Sex, male, n (%) 10 (62.5) 11 (55) 13 (65) 20 (58.8)
Age (years), mean ± SD 30.7 ± 11.4 35.5 ± 11.0 34.4 ± 12.7 31.7 ± 12.0
Patients with asthma, n (%) 0 (0) 2 (10) 7 (35) 0 (0)
Patients with positive skin prick test results, n (%) 0 (0) 5 (25) 8 (40) 0 (0)
Patients with aspirin sensitivity, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
SCGBs, secretoglobins; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps.
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sis system as described elsewhere [16]. Ten microscopic
fields were randomly selected from each slide under ×
400 magnification. Results were presented as 1/gray
scores, which positively correlate with the intensity of
immunoreactivity [16].
Statistical analysis
Results are presented as mean ± SD, or in box-and-
whisker plots. Paired sets of data were compared with
Mann-Whitney U-test. The Spearman test was used to
determine correlations. Paired t-test was used in tissue
culture data analysis. Data analyses were performed by
using SPSS for Windows (SPSS Inc., Chicago, IL, USA).
The level of significance was considered at a P value of
less than 0.05.
Results
The cytokine-driven regulation of SCGBs mRNA
expression in normal nasal mucosa
Since our previous studies have thoroughly investigated
the expression and regulation of SCGB1A1 (CC10) in
upper airways [5-7], we only detected the mRNA
expression profiles of other eight SCGBs in nasal
mucosa in the current study. Their mRNA expression
could be found in normal nasal mucosa except
SCGB1D2 (LIPB), whose expression could not be
detected even after 40 cycles of PCRs. As illustrated in
Figure 1, IL-1b,T N F - a, IL-4, and IL-13 inhibited,
whereas IFN-g promoted, SCGB3A2 (UGRP1) mRNA
expression in normal nasal mucosa. On the contrary,
IL-1b,T N F - a, IL-4, and IL-13 enhanced, whereas IFN-g
suppressed, SCGB2A1 (MGB2) mRNA expression.
Regarding SCGB1C1 (RYD5), IFN-g down-regulated and
IL-4 and IL-13 up-regulated its expression; however, no
significant effect was observed for IL-1b and TNF-a.
Nevertheless, as to SCGB1D4 (IIS), IL-1b,T N F - a,a n d
IFN-g increased, but IL-4 and IL-13 decreased, its
expression. With reference to SCGB1D1 (LIPA), its
expression could be induced by IL-1b and TNF-a but
depleted by IFN-g, and no significant effect was demon-
strated for IL-4 and IL-13. After stimulation with IL-1b,
TNF-a, and IFN-g, the expression of SCGB2A2 (MGB1)
was induced markedly; however, no significant effect
was discovered for IL-4 and IL-13. Finally, for SCGB3A1
(UGRP2), IL-1b, IL-4, and IL-13 enhanced whereas IFN-
g diminished its expression, and TNF-a exerted no sig-
nificant influence.
Table 2 Primers used for quantitative PCR analysis of SCGB genes expression
Gene Accession number Primers sequence Annealing temperature (˚C)
SCGB3A2
(UGRP1)
NM_054023 forward,5’-CGGAATTCCCCAGATAACTGTCA-3’ 60
reverse, 5’-ACATCTAGACACCAAGTGTGATAGC-3’
SCGB1C1
(RYD5)
NM_145651 forward, 5’-TGGCCCTCACCCTGTTCTGCATCT-3’ 60
reverse, 5’-CACCGTGCTGACTGCCCAGCAGTT-3’
SCGB1D1
(LIPA)
NM_006552 forward, 5’-CAGTGGTCTGCCAAGCTCTTGG-3’ 60
reverse, 5’- CATAGGCCATCGTATCCACGC-3’
SCGB1D2
(LIPB)
NM_006551 forward, 5’-CCTCTGTTCAAGTTAAGTC-3’ 58
reverse, 5’-CCGCAATGAGGCTTCGTTTGG-3’
SCGB1D4
(IIS)
NM_206998 forward, 5’-CTCACAGCCGAATAAGCCACC-3’ 55
reverse, 5’-GTGCAGGGCAAGTGATTTATTAAAGC-3’
SCGB2A1
(MGB2)
NM_002407 forward, 5’-CTCCTGGAGGACATGGTTG-3’ 60
reverse, 5’-CTATGTGACTGGTTGAGG-3’
SCGB2A2
(MGB1)
NM_002411 forward, 5’-GACAATGCCACTACAAATGCC-3’ 60
reverse, 5’-CATTGCTCAGAGTTTCATCCG-3’
SCGB3A1
(UGRP2)
NM_052863 forward, 5’- CGGAATTCCCCCGCGCCATGAAGCTC-3’ 66
reverse, 5’- ACATCTAGAGCCAAACACTGTCAGG-3’.
GAPDH NM_002046 forward,5’-GAAGGTGAAGGTCGGAGTC-3’ 60
reverse, 5’-GGAAGATGGTGATGGGATT-3’
SCGB, secretoglobin; UGRP1, uteroglobin-related protein 1; RYD5, ligand binding protein RYD5; LIPA, lipophilin A; LIPB, lipophilin B; IIS, interferon-g inducible
secretoglobin; MGB2, mammaglobin 2; MGB1, mammaglobin 1; UGRP2, uteroglobin-related protein 2.
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controls and CRS patients
The relative expression levels of different SCGBs in
sinonasal mucosa from controls, CRSsNP, and CRSwNP
patients are presented in Figure 2. The data shown in
Figure 2 are expressed as ΔCT (ΔCT = the difference in
threshold cycles for target and GAPDH). This is a direct
reflection of amount of input of target mRNA, and a
change of CT value of 1 unit is equal to a doubling, or
halving, of the level of target mRNA. The higher the
ΔCT value, the lower the level of target mRNA.
SCGB2A1 (MGB2) had the highest expression levels in
sinonasal mucosa from both controls and CRS patients.
The relative high expression levels were detected for
SCGB2A2 (MGB1), SCGB 1A1 (CC10), and SCGB3A1
(UGRP2) in sinonasal mucosa from controls and
CRSsNP patients. In CRSwNP patients, relative high
abundance of transcripts was found for SCGB1D4 (IIS).
As shown in Figure 3, compared with controls,
SCGB3A2 (UGRP1) and SCGB2A1 (MGB2) mRNA
expression was significantly down-regulated, whereas
SCGB2A2 (MGB1) mRNA expression was markedly up-
regulated, in both CRSsNP and CRSwNP with no signif-
icant difference between CRSsNP and CRSwNP. With
regard to SCGB1D4 (IIS), its expression was increased
in both CRSsNP and CRSwNP with a more prominent
Figure 1 The effect of cytokines on secretoglobins (SCGBs) mRNA expression in ex vivo cultured normal nasal mucosa.F o rd o s e
response experiments, the normal inferior turbinate tissues were incubated in the presence of TNF-a (1, 10, and 100 ng/ml), IL-1b (1, 10, and
100 ng/ml), INF-g (0.1, 1, and 10 ng/ml), IL-4 (1, 10, and 100 ng/ml), or IL-13 (1, 10, and 100 ng/ml) for 12 h. For time course experiments, the
tissues were incubated with TNF-a (20 ng/ml), IL-1b (20 ng/ml), IL-4 (20 ng/ml), IL-13 (20 ng/ml), or INF-g (1 ng/ml) for various time durations
between 4 and 24 h. n = 6. Results are expressed as mean ± SD.
#P < 0.05 and *P < 0.01 compared with untreated mucosa.
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(RYD5) was only increased, whereas the expression of
SCGB3A1 (UGRP2) was only decreased, in CRSwNP,
and there was a significant difference between CRSsNP
and CRSwNP. As to SCGB1D1 (LIPA), its expression
was only enhanced in CRSsNP in comparison with con-
trol. We did not detect the SCGB1D2 (LIPB) mRNA
expression in CRS either. Since the sample size of atopic
or asthmatic patients was not large enough in either
CRSsNP or CRSwNP group, we did not compare the
difference in SCGBs expression between atopic and
non-atopic patients, and asthmatic and non-asthmatic
patients.
SCGB3A2 (UGRP1) protein expression and its correlation
with inflammatory cells infiltration and clinical features in
CRS
We further studied the protein expression of SCGB3A2
(UGRP1) in CRS. Immunohistochemical staining
showed that SCGB3A2 (UGRP1) was mainly expressed
by epithelial cells (Figure 4A). Confirming the mRNA
data, we found that SCGB3A2 (UGRP1) protein expres-
sion was significantly decreased in both CRSsNP and
CRSwNP in comparison with controls and no significant
difference was found between CRSsNP and CRSwNP
(Figure 4B). The inflammatory cells infiltration was eval-
uated by hematoxylin and eosin staining. The numbers
of eosinophils, mononuclear cells, and total infiltrating
cells in the CRSsNP and CRSwNP group were listed
as following: 2.85 ± 1.73 vs. 7.15 ± 3.67 cells/HP
(P < 0.01), 32.30 ± 10.85 vs. 40.60 ± 13.80 cells/HP (P >
0.05), and 67.05 ± 18.06 vs. 76.25 ± 15.07 cells/HP (P >
0.05), respectively. Analyzing the relationship between
SCGB3A2 (UGRP1) staining intensity and the number
of inflammatory cells, we found that SCGB3A2
(UGRP1) staining intensity inversely correlated with the
number of total infiltrating cells (r = -0.485 and -0.558
in the CRSsNP and CRSwNP group, respectively; P <
0.05 for both), but did not correlate with the number of
eosinophils or mononuclear cells.
A significant negative correlation was found between
SCGB3A2 (UGRP1) staining intensity and pre-operative
CT scores (r = -0.54 and r = -0.45 in CRSsNP and
CRSwNP group, respectively; P < 0.05 for both), but not
pre-operative symptom scores. After surgery, eighteen
CRSsNP patients and 19 CRSwNP patients completed 1-
year follow-up records. We found that SCGB3A2
(UGRP1) staining intensity inversely correlated with
post-operative endoscopy scores (r = -0.50 and P <0 . 0 5
in CRSsNP; r = -0.58 and P <0 . 0 1i nC R S w N P ) ,o v e r a l l
VAS symptom scores (r = -0.54 and r = -0.47 in
CRSsNP and CRSwNP group, respectively; P <0 . 0 5f o r
both), and total VAS symptom scores (r = -0.53 and r =
-0.46 in CRSsNP and CRSwNP group, respectively; P <
0.05 for both). The data of CT, VAS, and endoscopy
scores are provided in Table 3.
Discussion
In the present study, extending our previous finding of
SCGB1A1 (CC10) [5,6], we demonstrated the cytokine-
driven expression regulation of SCGB superfamily mem-
bers in human upper airways and their overall expres-
sion profile in CRS for the first time. We detected the
mRNA expression of all SCGBs except SCGB1D2
(LIPB) in sinonasal mucosa. The expression of
SCGB1D2 (LIPB) is also absent in normal lung tissues
[1], suggesting that this SCGB may be not important for
airway functions. We confirmed the mRNA expression
of SCGB2A1 (MGB2) in nasal mucosa, which has been
demonstrated by previous gene array studies [6,18]. Our
unpublished data indicate that SCGB2A1 (MGB2) is
expressed by submucosal glands in sinonasal mucosa.
Previous investigations have also indentified some of dif-
ferent SCGBs in other parts of the human respiratory
tract, such as SCGB3A2 (UGRP1) and SCGB3A1
(UGRP2) in the epithelium of lung, and SCGB2A2
(MGB1) in trachea [1,19,20]. Our current study demon-
strated that in sinonasal mucosa SCGB3A2 (UGRP1)
was also mainly produced by epithelial cells. By contrast,
SCGB1C1 (RYD5) and SCGB1D4 (IIS) have, to the
Figure 2 Relative mRNA expression levels of different SCGBs in sinonasal mucosa. The relative expression levels are expressed as ΔCT (ΔCT
= the difference in threshold cycles for target and GAPDH). This is a direct reflection of amount of input of target mRNA, and a change of CT
value of 1 unit is equal to a doubling, or halving, of the level of target mRNA. The higher the ΔCT value, the lower the level of target mRNA. In
control group, n = 16; in chronic rhinosinusitis without nasal polyps (CRSsNP) group, n = 20; and in chronic rhinosinusitis with nasal polyps
(CRSwNP) group, n = 20. Results are presented as mean ± SD.
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human respiratory airway mucosa until now, although
SCGB1C1 (RYD5) and SCGB1D4 (IIS) have been
detected in Bowman’s glands of rat olfactory mucosa
and human lymphoid tissues and cells, respectively
[3,21]. The cellular locations of SCGB1C1 (RYD5) and
SCGB1D4 (IIS) in sinonasal mucosa are unclear. Due to
the lack of commercially available antibodies, further
in situ hybridization study may be helpful in clarifying
their cellular locations. The expression regulation of
Figure 3 The mRNA expression profiles of secretoglobins (SCGBs) in chronic rhinosinusitis (CRS). In control group, n = 16; in CRS without
nasal polyps (CRSsNP) group, n = 20; and in CRS with nasal polyps (CRSwNP) group, n = 20. Data are presented in box-and-whisker plots. *P <
0.05; **P < 0.01.
Lu et al. Respiratory Research 2011, 12:28
http://respiratory-research.com/content/12/1/28
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proinflammatory, and Th1 and Th2 relevant cytokines
play a crucial role. The increased expression of IL-1b,
TNF-a,I N F - g, and IL-4 has been demonstrated in CRS,
which may be involved in the inflammation perpetuation
a n de x a g g e r a t i o n[ 5 ] .T h e r e f o r e ,i nt h i ss t u d y ,S C G B s
expression regulation by these cytokines was studied
in nasal mucosa. Limited studies have indicated that
IL-4 and IL-13 can induce, whereas INF-g can inhibit
the expression of SCGB3A1 (UGRP2) in a mouse trans-
formed Clara cell line [22]; IL-5 may suppress
SCGB3A2 (UGRP1) expression in murine lung tissues
in vivo [23]; and INF-g can up-regulate SCGB1D4 (IIS)
expression in human lymphoblast cells [3]. In the pre-
sent study, we found that SCGBs expression in human
nasal mucosa could be differentially modulated by var-
ious inflammatory cytokines. On the other hand, the
same cytokine could evoke distinct responses of differ-
ent SCGB genes. Our results suggest that the expression
of SCGBs is finely controlled by local immune responses
in airways and SCGBs may be involved in cytokine-
induced airway inflammation.
In present study, we found altered expression profiles
of SCGBs in CRS. Since the biological functions of
SCGBs are poorly understood, their roles in CRS mostly
remain speculative. The unique increase of SCGB1C1
(RYD5) and decrease of SCGB3A1 (UGRP2) in
CRSwNP, but not in CRSsNP, suggest that these two
SCGBs may be more particularly involved in the polyp
formation. Choi et al found that SCGB1D4 (IIS) can
modulate lymphoblast cell migration [3]; therefore, the
enhanced expression of SCGB1D4 (IIS) in both CRSsNP
and CRSwNP may contribute to the persistent immune
responses in CRS. The expression of SCGB1D1 (LIPA),
SCGB2A1 (MGB2), and SCGB2A2 (MGB1) has been
shown to be upregulated in human lung cancers [1,2].
In the current study, we found that SCGB2A2 (MGB1)
expression was upregulated, whereas SCGB2A1 (MGB2)
expression was down-regulated in both CRSsNP and
CRSwNP, which is consistent with our previous gene
array data [6]. In addition, we found that SCGB1D1
(LIPA) expression was up-regulated in CRSsNP. The
aberrant expression of these three SCGBs suggests that
they may be related to epithelial proliferation and tissue
hyperplasia in CRS. However, obviously, further studies
are needed to test these hypotheses and to elucidate the
roles of SCGBs in CRS.
Among SCGBs, SCGB3A2 (UGRP1) is particularly
interesting, given its structure and function similarities
with SCGB1A1 (CC10) [4,9]. SCGB3A2 (UGRP1) is
highly specific for airways [4,9]. Although the decreased
expression and an anti-inflammatory role of SCGB3A2
(UGRP1) in allergic airway inflammation was observed
in an animal model [4,9], its involvement in human
Figure 4 The protein expression of secretoglobin 3A2 (SCGB3A2) (uteroglobin-related protein 1, UGRP1) in chronic rhinosinusitis
(CRS). A: A)-C) Representative photomicrographs of SCGB3A2 (UGRP1) immunohistochemical staining of sinonasal tissue sections from A)
control, B) CRS without nasal polyps (CRSsNP), and C) CRS with nasal polyps (CRSwNP); D) A photomicrograph of a section stained with a
control antibody. Scale bars, 50 μm. B: Quantification of protein expression levels of SCGB3A2 (UGRP1) examined by immunohistochemistry.
Immunostaining intensity was analyzed using the automated image analysis system. Results are presented as 1/gray scores, which positively
correlate with the intensity of immunoreactivity. In control group, n = 16; in CRSsNP group, n = 20; and in CRS CRSwNP group, n = 20. Data are
presented in box-and-whisker plots. *P < 0.05.
Table 3 Disease severity assessment
CRSsNP CRSwNP
Pre-operation
CT scores 8.40 ± 4.21 14.90 ± 5.69
Endoscopy scores 4.55 ± 1.90 7.05 ± 2.04
Overall VAS scores 6.15 ± 1.39 7.15 ± 1.48
Total VAS scores 23.35 ± 5.09 23.90 ± 4.78
Post-operation
Endoscopy scores 1.61 ± 1.33 3.05 ± 2.22
Overall VAS scores 2.33 ± 2.28 3.11 ± 1.73
Total VAS scores 5.72 ± 5.44 7.68 ± 6.29
CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic
rhinosinusitis with nasal polyps.
Pre-operation, in CRSsNP group, n = 20; and in CRSwNP group, n = 20.
Post-operation, in CRSsNP group, n = 18; and in CRSwNP group, n = 19.
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found that the mRNA and protein expression of
SCGB3A2 (UGRP1) was dramatically down-regulated in
both CRSsNP and CRSwNP, and SCGB3A2 (UGRP1)
was mainly produced by epithelial cells in sinonasal
mucosa, which is similar to the expression pattern of
SCGB1A1 (CC10) [5-7]. Contrast to our findings, Bur-
bure et al found that SCGB3A2 (UGRP1) levels in spu-
tum were increased in patients with asthma and rhinitis
[24]. However, they did not examine the SCGB3A2
(UGRP1) expression in local mucosa and the protein
levels in sputum may not correlate with the expression
intensity in local mucosa. As shown in our current study,
SCGB3A2 (UGRP1) expression could be modulated by
proinflammatory, Th1 and Th2 cytokines in nasal
mucosa; therefore, the decreased expression of SCGB3A2
(UGRP1) in CRS might relate to the specific local cyto-
kine environment in CRS [5,25]. More importantly, we
found significant negative correlations between
SCGB3A2 (UGRP1) expression and total inflammatory
cells infiltration and disease severity evaluated by CT
scan. In the light of the potential anti-inflammatory func-
tion of SCGB3A2 (UGRP1) indicated by animal experi-
ments, our results suggest that the loss of SCGB3A2
(UGRP1) expression may contribute to the hyper-inflam-
mation in CRS. However, this needs to be validated by
function studies in human subjects in future. Further-
more, we found that SCGB3A2 (UGRP1) levels negatively
correlated with post-operative symptom and endoscopy
scores. This would be of considerable clinical value. Since
detecting of potential responders among candidates for
surgical treatment by certain biomarkers remains a diffi-
cult task [26]. This finding not only suggests that
S C G B 3 A 2( U G R P 1 )m a yb eap r e d i c t o ro fs u r g i c a l
response but also strengthens the involvement of
SCGB3A2 (UGRP1) in the pathogenesis of CRS.
In this study, inferior turbinates were used as control,
because it is difficult to obtain enough normal ethmoid
mucosa samples due to ethical consideration. It is
known that sinus and turbinate mucosa are both cov-
ered by the respiratory epithelium and share a number
of similarities in histology and expression profiles of
many common and important immune and biological
molecules. Although we are not able to rule out the
possibility that the differences observed between con-
trols and CRS might be influenced by comparing these
different tissue localizations, one could see clear differ-
ences between ethmoid tissue obtained from CRSsNP
and CRSwNP patients.
In conclusion, this study, for the first time, shows the
expression features of SCGB superfamily members in
CRS and their cytokine-driven regulation in upper air-
ways. Our results suggest the reduced production of
SCGB3A2 (UGRP1), which is likely due, at least in part,
to a local inflammatory environment, may contribute to
the hyperinflammation in CRS and correlates with
response to surgery.
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